ZA201200390B - Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein - Google Patents

Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein

Info

Publication number
ZA201200390B
ZA201200390B ZA2012/00390A ZA201200390A ZA201200390B ZA 201200390 B ZA201200390 B ZA 201200390B ZA 2012/00390 A ZA2012/00390 A ZA 2012/00390A ZA 201200390 A ZA201200390 A ZA 201200390A ZA 201200390 B ZA201200390 B ZA 201200390B
Authority
ZA
South Africa
Prior art keywords
inhibitor
crystalline forms
solid oral
oral formulations
apoptosis protein
Prior art date
Application number
ZA2012/00390A
Other languages
English (en)
Inventor
Jeewan Thakur
Dong Yang
Lili Feng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42937834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201200390(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA201200390B publication Critical patent/ZA201200390B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA2012/00390A 2009-08-12 2012-01-18 Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein ZA201200390B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27405109P 2009-08-12 2009-08-12
PCT/EP2010/061679 WO2011018474A1 (en) 2009-08-12 2010-08-11 Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein

Publications (1)

Publication Number Publication Date
ZA201200390B true ZA201200390B (en) 2012-10-31

Family

ID=42937834

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/00390A ZA201200390B (en) 2009-08-12 2012-01-18 Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein

Country Status (24)

Country Link
US (4) US8623385B2 (enExample)
EP (1) EP2464644A1 (enExample)
JP (3) JP2013501751A (enExample)
KR (2) KR20120048008A (enExample)
CN (2) CN105646471A (enExample)
AR (1) AR077869A1 (enExample)
AU (4) AU2010283748A1 (enExample)
BR (1) BR112012003118A2 (enExample)
CA (1) CA2769616A1 (enExample)
CL (1) CL2012000349A1 (enExample)
CO (1) CO6612189A2 (enExample)
IL (1) IL217760A0 (enExample)
IN (1) IN2012DN00858A (enExample)
MA (1) MA33511B1 (enExample)
MX (2) MX2012001844A (enExample)
MY (1) MY160475A (enExample)
PE (2) PE20121132A1 (enExample)
PH (1) PH12014501890B1 (enExample)
RU (1) RU2671196C1 (enExample)
SG (1) SG177713A1 (enExample)
TN (1) TN2012000026A1 (enExample)
TW (1) TWI607006B (enExample)
WO (1) WO2011018474A1 (enExample)
ZA (1) ZA201200390B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311867A (zh) 2016-04-20 2019-02-05 葛兰素史克知识产权开发有限公司 包含ripk2抑制剂的共轭物
CN108484640B (zh) * 2018-05-22 2020-09-15 南京华威医药科技集团有限公司 一种抗肿瘤的细胞凋亡蛋白抑制剂
BR112020024296A2 (pt) 2018-08-27 2021-03-09 Regeneron Pharmaceuticals, Inc. Métodos para produção de um intermediário de purificação de proteína concentrado, para monitoramento e controle dos atributos de qualidade críticos em um intermediário de purificação de proteína e para monitorar e controlar os níveis de excipientes no fluido de cultura de células colhido e/ou intermediário de purificação de proteína, e, intermediário de purificação de proteína
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119060A1 (en) * 2001-08-10 2003-06-26 Desrosiers Peter J. Apparatuses and methods for creating and testing pre-formulations and systems for same
CA2491041A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
EP2253614B1 (en) * 2004-04-07 2012-09-19 Novartis AG Inhibitors of IAP
ATE477254T1 (de) * 2004-12-20 2010-08-15 Genentech Inc Pyrrolidine als inhibitoren von iap
PE20110224A1 (es) * 2006-08-02 2011-04-05 Novartis Ag PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO

Also Published As

Publication number Publication date
RU2671196C1 (ru) 2018-10-30
AR077869A1 (es) 2011-09-28
CN105646471A (zh) 2016-06-08
US20180370960A1 (en) 2018-12-27
JP2018172403A (ja) 2018-11-08
EP2464644A1 (en) 2012-06-20
US20170081319A1 (en) 2017-03-23
CA2769616A1 (en) 2011-02-17
MX2012001844A (es) 2012-02-29
PE20121132A1 (es) 2012-09-04
AU2010283748A1 (en) 2012-02-09
CN102471331B (zh) 2016-01-13
US9540363B2 (en) 2017-01-10
TW201118091A (en) 2011-06-01
MY160475A (en) 2017-03-15
AU2016203145A1 (en) 2016-06-02
AU2017254950A1 (en) 2017-11-23
MX351274B (es) 2017-10-06
US8623385B2 (en) 2014-01-07
KR20120048008A (ko) 2012-05-14
US20140093570A1 (en) 2014-04-03
KR20180020315A (ko) 2018-02-27
PH12014501890A1 (en) 2015-09-14
IL217760A0 (en) 2012-03-29
AU2017254950B2 (en) 2018-09-20
US10093665B2 (en) 2018-10-09
TN2012000026A1 (en) 2013-09-19
PE20170777A1 (es) 2017-07-04
TWI607006B (zh) 2017-12-01
IN2012DN00858A (enExample) 2015-07-10
US20120128742A1 (en) 2012-05-24
CL2012000349A1 (es) 2012-09-07
JP2016179976A (ja) 2016-10-13
JP2013501751A (ja) 2013-01-17
WO2011018474A1 (en) 2011-02-17
MA33511B1 (fr) 2012-08-01
SG177713A1 (en) 2012-02-28
CN102471331A (zh) 2012-05-23
CO6612189A2 (es) 2013-02-01
RU2012108931A (ru) 2013-09-27
PH12014501890B1 (en) 2015-09-14
BR112012003118A2 (pt) 2016-02-23
WO2011018474A8 (en) 2011-09-22
AU2014213533A1 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
GB2480042B (en) Solid oral unit-dosage prebiotic forms and methods of use
EP3363797B8 (en) Oral dosage form of apoptosis signal-regulating kinase inhibitors
PL2335643T3 (pl) Część do czyszczenia jamy ustnej urządzenia do czyszczenia jamy ustnej oraz urządzenie do czyszczenia jamy ustnej
IL213938A0 (en) Compositions and methods for assessing cytotoxicity of single cells
EP2453827A4 (en) SYSTEM AND METHODS FOR PRESERVING AN ORAL MOUTH
ZA201107847B (en) Oral compositions containing polyguanidinium compounds and methods of manufacture and use thereof
PT2173345E (pt) Formulação oral de metadoxina
EP2425276A4 (en) Compositions and methods for determining directionality of radiation
PL2506840T3 (pl) Zastosowania inhibitorów czynnika indukowalnego niedotlenieniem
ZA201104894B (en) Solid oral formulations of a pyridopyrimidinone
IL206577A0 (en) Formulations of flibanserin
ZA201004144B (en) Fatty acid by-products and methods of using same
EP2435052A4 (en) SOLID PHARMACEUTICAL FORMS OF LAMIVUDIN ORAL ADMINISTRATION
IL217760A0 (en) Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein
IL217135A0 (en) Stabilized herbicidal formulations and methods of use
EP2503902A4 (en) SWEETENER COMPOSITIONS AND METHOD FOR THEIR MANUFACTURE
BG110103A (bg) Супресор на ендогенния човешки гама - интерферон
IL209833A0 (en) Solid dosage formulations of telcagepant potassium
PT2411376E (pt) Inibidores de nf-kb
EP2381950A4 (en) COMPOSITIONS AND METHOD FOR THEIR USE
HK1166312A (en) Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein
ZA201106054B (en) Anti bone-loss and anti attachment-loss effects of an oral composition
IL215486A0 (en) Compositions of cholinesterase inhibitors
HK1166703A (en) Oral formulations of bendamustine
HK1166785A (en) Salt of abt-263 and solid-state forms thereof